Skip to main content
Equibles
SIBN logo

SIBN · SI-BONE, Inc.

Track SIBN — free

Use SIBN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SIBN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.44 -0.70 (-2.90%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$1.06B
Shares
45.11M
Volume · Nov 13 443.71K Avg daily vol (3M) 688.01K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$23.44 Open$24.40 Day$23.40–24.68 52W close$11.61–25.60 Avg vol 30d825K Short int4.5M · 10.0% of shares · 6.8d Short vol30% Last earningsNov 2, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Next earnings call
Feb 22, 2027 Est · unconfirmed · in 14 wks
Q3 2026 earnings call transcript
call held Nov 2, 2026
Play latest call

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Procedure volumes rose 19.5% as revenue increased

SI-BONE's revenue for the three months ended September 30, 2026 rose 14.5%, driven by a 19.5% increase in procedure volumes, while gross margin declined to 79.3%. Nine-month revenue rose 13.6%, but the company reported a $12.0 million net loss.

Revenue $55.7M ▲ 14.5% Net loss $3.62M Diluted EPS -$0.08
Read from the MD&A section
5 source passages
The increase in revenue for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025 was primarily driven by a $6.4 million increase in U.S. revenue due to increased sales channel coverage, and 19.5% increase in procedure volumes, including strong growth in demand from interventional spine physicians in the ASC and OBL settings. Revenue | 55,704 | | 48,656 | | 7,048 | 14.5% Gross margin was 79.3% for the three months ended September 30, 2026 compared to a gross margin of 79.8% for the three months ended September 30, 2025 due to changes in site of care and procedure mix. Revenue | 164,302 | | 144,576 | | 19,726 | 13.6% During the nine months ended September 30, 2026, we incurred a net loss of $12.0 million. Open the document at this passage
Nov 2
Current report 8-K
Third-quarter revenue grows 14.5%, 2026 guidance reaffirmed

SI-BONE reported third-quarter revenue of $55.7 million, up 14.5%, positive adjusted EBITDA of $3.0 million and reaffirmed 2026 revenue guidance of $231M - $233M with ~15-16% growth and ~79.0% gross margin.

Financial results
6 source passages
SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended September 30, 2026. Worldwide revenue of $55.7 million, representing growth of 14.5% Positive adjusted EBITDA of $3.0 million, representing an improvement of 32.4% SI-BONE reaffirms its previously issued 2026 worldwide revenue and gross margin guidance. Revenue | $231M - $233M<br><br>~15-16% growth Gross Margin | ~79.0% Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$220.65M
Trailing 12 months
Net income (TTM)
−$13.69M
Trailing 12 months
Revenue growth YoY
+14.5%
Year over year
Operating margin
-7.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$346,000
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.0%
Year over year · more shares
Price change (1Y)
+35.8%
Trailing year
Short interest
10.0%
Latest settlement · 6.8 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲26.1% $49.00M −$4.50M '24 Q4* ▲24.9% $47.29M −$6.54M '25 Q1 ▲21.7% $48.63M −$6.15M '25 Q2 ▲20.6% $48.66M −$4.57M '25 Q3 ▲15% $56.35M −$1.64M '25 Q4* ▲11.2% $52.59M −$4.33M '26 Q1 ▲15.2% $56.01M −$4.09M '26 Q2 LATEST ▲14.5% $55.70M −$3.62M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 3, 2026
Q2 FY26

TL;DR. SI-BONE delivered ~15% Q2 revenue growth and a 178% adjusted EBITDA improvement while raising the low end of 2026 revenue guidance to $231–$233M and lowering the operating expense growth assumption to ~12%. The company filed a 510(k) for a third breakthrough product targeting complex spine procedures and highlighted finalized CMS reimbursement tailwinds, including new MS-DRGs for Granite effective October 1.

Bullish
  • + Q2 adjusted EBITDA improved 178% to $2.8M with revenue growing ~2x operating expenses.
  • + Submitted 510(k) for a third breakthrough device targeting complex spine procedures, with phased launch planned for Q4 2026.
  • + CMS finalized new MS-DRGs for complex spinal fusion incorporating Granite, with potential hospital payment increase up to $50,000 per procedure, effective October 1.
Bearish
  • − Guidance raise reflects measured approach; management is not assuming material Q4 contribution from the new product launch or reimbursement tailwinds.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +40%
above
Price vs 50-day avg +15%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 85%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +19%
trailing
6-month return +60%
trailing
YTD return +19%
this year
Relative strength +59%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $20 › 200d $17 — 50d above 200d
Institutional flow Accumulating
140 of 169 funds reported for Sep 30 · net +1.4M sh shares · +19 new
Insider flow Distributing
Net -$861.8K over 90 days · 100% sells
Short interest Falling
10.03% of shares out · ▼ -3.8% MoM · 6.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
169 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Excellent
Revenue growth +22%
Y/Y
Gross margin 238%
contracting
EPS growth +41%
Y/Y
Free cash flow $-9.1M
Balance sheet $6.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 50%
annualized · 1-yr
Max drawdown −46%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the 8-K filed Nov 2, 2026
Revenue · Fiscal Year 2026 Maintained $231M – $233M
Aug 3, 2026 $231M – $233M changed to Nov 2, 2026 $231M – $233M
prior FY $200.93M midpoint +15.5% Y/Y
Gross Margin · Fiscal Year 2026 Maintained 79%
Aug 3, 2026 79% changed to Nov 2, 2026 79%
Operating Expenses · Fiscal Year 2026 Lowered 10.5%
Aug 3, 2026 12% changed to Nov 2, 2026 10.5%
Previous outlook earlier release · from the Earnings Call filed May 11, 2026

Still-open targets the latest release did not restate under the same label.

Full-year operating expenses growth · full-year 2026 12.5%
Guided vs delivered · last 8 settled
Worldwide revenue Fiscal Year 2025
guided $198M – $200M
$200.93M Beat +1.0%
Worldwide revenue 2024
guided $165M – $167M
$167.18M Beat +0.7%
Worldwide revenue 2023
guided $136M – $137M
$138.89M Beat +1.7%
Worldwide revenue 2022
guided $104M – $105M
$106.41M Beat +1.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+40% Bullish
Price vs 50-day avg
+15% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
85% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $20 › 200d $17 — 50d above 200d
Institutional flow Accumulating
140 of 169 funds reported for Sep 30 · net +1.4M sh shares · +19 new
Insider flow Distributing
Net -$861.8K over 90 days · 100% sells
Short interest Falling
10.03% of shares out · ▼ -3.8% MoM · 6.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
169 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $12 Now $23 · 85% Range high $26
vs 200-day avg +40% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Active U.S. physicians 1,715 Q2 2026 —
Adjusted EBITDA non-GAAP 2.84M Q2 2026 —
GAAP → non-GAAP reconciliation
GAAP Net loss -4.09M
-1.33M Interest income
+598K Interest expense
+1.68M Depreciation and amortization
+5.98M Stock-based compensation
= Adjusted EBITDA 2.84M
Free cash flow non-GAAP -4.21M Six months ended June 30, 2026 —
Gross margin 79.5% Q2 2026 —
Procedure volume growth 14.9% Q2 2026 —
Trailing 12-month average revenue per territory 2.2M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SIBN
SI-BONE, Inc.
this stock
$1.06B +18.9% +21.5% — 10.0%
ABT
Abbott Laboratories
 $187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
176
% held
109.2%
Reported
140 of 169
Top holder
First Light Asset Managem…
Held Float
View
Held by Funds
Fund positions
187
View
Short & Settlement
Short Interest Falling
Shares short
4.5M
Days to cover
6.8d
Change
-178.4K sh
View
Short Volume
Short vol %
30%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$19.2K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
31.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$861.8K
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$200.9M
Net income (FY)
$-18.9M
EPS diluted
$-0.44
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 3, 2026
This year
16

SI-BONE's revenue for the three months ended September 30, 2026 rose 14.5%, driven by a 19.5% increase in procedure volumes, while gross margin declined to 79.3%. Nine-month revenue rose 13.6%, but the company reported a $12.0 million net loss.

View
Proposed Sales
Value
$125.3K
Shares
5.3K
Filed
Nov 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
SI-BONE, Inc. Reports Financial R…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
SIBN -3.3% +19.1% +59.8% +10.4% +18.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -5.9% +20.3% +59.3% +10.6% +8.2%
Key facts CIK 1459839 CUSIP 825704109 13F (30d) 133 filings 118 filers Visit website Investor relations